Second-line treatment of first relapse recurrent ovarian cancer

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 50, Issue 5, 2010, Pages 465-471

  Chua, Terence C ^a,b   Liauw, Winston ^b   Robertson, Gregory ^c   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Nepean Cancer Care Centre   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Cytoreductive surgery; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM; TOPOTECAN;

ADD ON THERAPY; ALOPECIA; ANEMIA; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; HUMAN; HYPERTHERMIC THERAPY; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PERITONEUM CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650190691     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2010.01209.x     Document Type: Review

References (50)

1. AIHW, NBCC. Ovarian Cancer in Australia: An Overview, 2006. Canberra: AIHW, 2006.
2. Earle CC, Schrag D, Neville BA et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006 (Feb. 1);98(3):172-180.
3. Chan JK, Tian C, Teoh D et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol In Press, Corrected Proof 2010 (Mar); 116(3):307-311. Epub 2009 Nov. 27.
4. Winter WE III, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 (Aug. 20);25(24):3621-3627.
5. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. The Lancet 2003;361(9375):2099-2106.
6. Dizon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002 (Mar. 1); 20(5):1238-1247.
7. Markman M, Markman J, Webster K et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004 (Aug. 1); 22(15):3120-3125.
8. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 2002;7(Suppl. 5):11-19.
9. Vergote I, Rustin GJS, Eisenhauer EA et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst 2000 (Sep. 20); 92(18):1534-1535.
10. Rustin GJ, van der Burg ME, on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009;27(18s): Abstr 1.
11. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006 (Oct. 10); 24(29):4699-4707.
12. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005 (May 1); 16(5):749-755.
13. Bolis G, Scarfone G, Giardina G et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin-or carboplatin- sensitive ovarian cancer. Gynecol Oncol 2001;81(1):3-9.
14. Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008;108(1):90-94.
15. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998 (Dec. 1); 9(12):1343-1345.
16. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 (Mar. 1); 15(3):987-993.
17. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996 (May 1); 14(5):1552-1557. (Pubitemid 26134213)
18. Miller DS, Blessing JA, Krasner CN et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a Study of the Gynecologic Oncology Group. J Clin Oncol 2009 (Jun. 1); 27(16):2686-2691.
19. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. The Lancet 2009;374(9698):1331-1338.
20. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 (Nov. 20); 25(33):5165-5171.
21. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008 (Jan 1); 26(1):76-82.
22. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007 (Nov. 20); 25(33):5180-5186.
23. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia. Gynecol Oncol 2008;110(1):49-55.
24. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, Monk BJ, Greer BE, Boente M, Liang SX. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. Meeting: 2010 ASCO Annual Meeting Citation J Clin Oncol 28:18 s: 2010 (suppl; abstr LBA1).
25. Chun YS, Vauthey J-N, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009 (Dec. 2); 302(21):2338-2344.
26. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977;61:1307-1317.
27. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
28. Blythe JG, Wahl TP. Debulking surgery: does it increase the quality of survival?. Gynecol Oncol 1982;14:396-408.
29. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002 (Mar. 1); 20(5):1248-1259.
30. Grossi M, Quinn MA, Thursfield VJ et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust 2002;177:11-16.
31. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112:265-274.
32. Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 1995;76(9):1606-1614.
33. Harter P, Bois Ad, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006 (Dec); 13(12):1702-1710.
34. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009 (May); 16(5):1324-1330.
35. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-1939.
36. Ritu S, Antonio S, Marianna LZ et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Cancer 2007;109(4):685-691.
37. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage iii ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(4):1001-1007.
38. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 (Jan 5); 354(1):34-43.
39. Trimble EL, Christian MC. National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2008 (Mar-Apr); 18 (Suppl. 1):26-28.
40. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980 (Feb. 1); 40(2):256-260.
41. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 2007 (Aug); 23(5):431-442.
42. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009;135(12):1432-1435.
43. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003 (Oct. 15); 21(20):3737-3743.
44. Bereder JM, ed. HIPEC in Ovarian Cancer - French Experience. Lyon: 6th Workshop on Peritoneal Surface Oncology, 2008.
45. Walker JL. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol 2009;112(3):439-440.
46. Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2006;100:27-32.
47. Ohtsubo T, Saito H, Tanaka N et al. Enhancement of cisplatin sensitivity and platinum uptake by 40°C hyperthermia in resistant cells. Cancer Lett 1997;119(1):47-52.
48. Chua TC, Liauw W, Robertson G et al. Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol 2009;114(1):137-139.
49. Chi DS, Schwartz PE. Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol 2008;111(3):391-399.
50. Crandon AJ, Obermair A. Advanced cytoreductive surgery: Asia Pacific perspective. Gynecol Oncol 2009;114: S15-S21.